Long-term primary results of accelerated partial breast irradiation after breast-conserving surgery for early-stage breast cancer: a randomised, phase 3, equivalence trial

Publication date: Available online 5 December 2019Source: The LancetAuthor(s): Frank A Vicini, Reena S Cecchini, Julia R White, Douglas W Arthur, Thomas B Julian, Rachel A Rabinovitch, Robert R Kuske, Patricia A Ganz, David S Parda, Michael F Scheier, Kathryn A Winter, Soonmyung Paik, Henry M Kuerer, Laura A Vallow, Lori J Pierce, Eleftherios P Mamounas, Beryl McCormick, Joseph P Costantino, Harry D Bear, Isabelle GermainSummaryBackgroundWhole-breast irradiation after breast-conserving surgery for patients with early-stage breast cancer decreases ipsilateral breast-tumour recurrence (IBTR), yielding comparable results to mastectomy. It is unknown whether accelerated partial breast irradiation (APBI) to only the tumour-bearing quadrant, which shortens treatment duration, is equally effective. In our trial, we investigated whether APBI provides equivalent local tumour control after lumpectomy compared with whole-breast irradiation.MethodsWe did this randomised, phase 3, equivalence trial (NSABP B-39/RTOG 0413) in 154 clinical centres in the USA, Canada, Ireland, and Israel. Adult women (>18 years) with early-stage (0, I, or II; no evidence of distant metastases, but up to three axillary nodes could be positive) breast cancer (tumour size ≤3 cm; including all histologies and multifocal breast cancers), who had had lumpectomy with negative (ie, no detectable cancer cells) surgical margins, were randomly assigned (1:1) using a biased-coin-based minimisation algorithm to rece...
Source: The Lancet - Category: General Medicine Source Type: research

Related Links:

ConclusionThe findings revealed the heterogeneity of sexual health among BC patients in China and may guide to identify the high-risk patients and enable early intervention.
Source: Supportive Care in Cancer - Category: Cancer & Oncology Source Type: research
This study aimed to investigate the associations between total and subclasses of flavonoid and breast cancer risk among Chinese population. This case-control study recruited 1522 eligible breast cancer cases and 1547 frequency-matched control subjects from June 2007 to July 2018 in Guangdong, China. Dietary intake was obtained by face-to-face interview using a validated food frequency questionnaire. Odds ratios and 95% confidence intervals were calculated by multivariable logistic regression models. After adjusting for potential confounders, inverse associations were observed between total flavonoids, anthocyanidins, proan...
Source: European Journal of Cancer Prevention - Category: Cancer & Oncology Tags: Breast cancer Source Type: research
Abstract The health benefits and risks of menopausal hormone therapy among women aged 50-59 years are examined in the Women's Health Initiative randomized, placebo-controlled trials using long-term follow-up data and a parsimonious statistical model that leverages data from older participants to increase precision. These trials enrolled 27,347 healthy post-menopausal women aged 50-79 at 40 U.S. clinical centers during 1993-1998, including 10,739 post-hysterectomy participants in a trial of conjugated equine estrogens, and 16,608 participants with uterus in the trial of these estrogens plus medroxyprogesterone acet...
Source: Am J Epidemiol - Category: Epidemiology Authors: Tags: Am J Epidemiol Source Type: research
Cancer treatments can be damaging to the ovary, with implications for future fertility and reproductive lifespan. There is therefore a need for a biomarker than can usefully provide an assessment of the ovary and its potential for long-term function after cancer treatment, and ideally also be of value pre-treatment, for the prediction of post-treatment function. In this review we assess the value of anti-Müllerian hormone (AMH) in this context. Measurement of AMH at the time of cancer diagnosis has been shown to be predictive of whether or not there will remain some ovarian function post-treatment in women with breast...
Source: Frontiers in Endocrinology - Category: Endocrinology Source Type: research
AbstractPurposeTo examine the association between obesity measured by body mass index (BMI) and waist circumference (WC) according to menopausal status in Korean women.MethodsWe identified 6,467,388 women, using the Korean National Health Insurance System Cohort. Cox-proportional hazard models were used to generate adjusted hazard ratios (aHRs) and 95% confidence intervals (CIs) for breast cancer risk in relation to BMI and WC.ResultsIn postmenopausal women, the risk of breast cancer increased with BMI. Compared to women with a BMI of 18.5 –23 kg/m two, the risk of invasive breast cancer was lower in patients with BMI 
Source: Breast Cancer Research and Treatment - Category: Cancer & Oncology Source Type: research
In this issue of the Journal, a group of distinguished Nordic researchers, led by Anne Helene Garde and including four of our Associated Editors, present a discussion paper that originated from a workshop and provides detailed recommendations on night shift work (1). The recommendations are very clear: to protect workers ’ health, night shift schedules should have: (i) ≤3 consecutive night shifts; (ii) shift intervals of ≥11 hours; and (iii) ≤9 hours shift duration. For pregnant women, night work should be limited to one shift per week. The authors acknowledge that under circumstances allowing better possibi...
Source: Scandinavian Journal of Work, Environment and Health - Category: Occupational Health Tags: Editorial Source Type: research
Background: In PALOMA-3, endocrine therapy (ET)-sensitive (ie, documented clinical benefit from prior ET or 2 y adjuvant ET before recurrence) pts with HR+/HER2 – ABC and disease progression on prior ET derived overall survival (OS) benefit from palbociclib (PAL) + fulvestrant (FUL) vs placebo (PBO)+FUL. In pts who received prior chemotherapy (CT) for ABC, median (m)OS was similar between treatment arms, suggesting that prior CT impacts the benefit of PAL +FUL. This post hoc analysis reports OS and progression-free survival (PFS) in the ITT and ET-sensitive populations from PALOMA-3 with/without prior CT for ABC and ...
Source: European Journal of Cancer - Category: Cancer & Oncology Authors: Tags: PROFFERED PAPER SESSION: Proffered Paper Session Source Type: research
Background: Neoadjuvant endocrine treatment (NET) is increasingly used in early stage ER positive breast cancer (EBC) mainly in post-menopausal patients. This approach shows response rates (RR) comparable to neoadjuvant chemotherapy for some patients but randomised trials are limited. We set out to review the RR in patients treated with NET at our UK centre.
Source: European Journal of Cancer - Category: Cancer & Oncology Authors: Tags: POSTERS B: Systemic Treatment Source Type: research
Background: Aromatase inhibitors (AI ’s) are the gold standard adjuvant treatment for post-menopausal women with oestrogen-receptor positive breast cancer (BC) but accelerate bone loss and increase fracture risk.
Source: European Journal of Cancer - Category: Cancer & Oncology Authors: Tags: POSTERS B: Lifestyle, Prevention including Secondary Prevention Source Type: research
Selective estrogen receptor modulators (SERMs) are an increasingly important therapeutic modality that are used by clinicians on a daily basis. Unfortunately, clinicians have a limited understanding regarding the underlying mechanism(s) of how SERMs function and their increasingly useful role in the treatment of estrogen-responsive target tissues such as the breast, bone, vagina, uterine endometrium, and brain. This review will provide a basic understanding of our current knowledge of SERM pharmacodynamics and will highlight the clinical applications of Food and Drug Administration–approved SERMs in the treatment of ...
Source: Menopause - Category: OBGYN Tags: Clinical Corner: Invited Review Source Type: research
More News: Brachytherapy | Breast Cancer | Breast Conservation Surgery | Breast Lumpectomy | Canada Health | Cancer | Cancer & Oncology | Chemotherapy | Department of Health | General Medicine | Hormones | Ireland Health | Israel Health | Lumpectomy | Mastectomy | Men | Menopause | Middle East Health | Radiation Therapy | Statistics | Toxicology | Women